Neogen Corporation (NASDAQ:NEOG), a leader in food and animal safety solutions, reported financial results for its fiscal third quarter of 2026 that presented a mixed picture for investors. While the company exceeded analyst expectations on the top and bottom lines, a sharp decline in its Animal Safety segment and a lowered full-year profit outlook appear to be driving a negative market reaction.
Earnings vs. Estimates: A Top and Bottom Line Beat
For the quarter, Neogen delivered a clear outperformance relative to Wall Street forecasts. The company reported revenue of $211.2 million, surpassing the analyst consensus estimate of $208.6 million. On a non-GAAP basis, adjusted earnings per share (EPS) came in at $0.09, significantly higher than the estimated $0.06.
- Reported Revenue: $211.2 million
- Estimated Revenue: $208.6 million
- Reported Adj. EPS: $0.09
- Estimated Adj. EPS: $0.06
This beat was primarily fueled by strength in the company's core Food Safety segment, which saw revenue grow 2.6% year-over-year to $156.7 million, with particular strength in indicator testing and culture media products.
Segment Performance: A Tale of Two Businesses
The quarterly results highlighted a stark divergence between Neogen's two main divisions.
- Food Safety: This segment showed resilience and growth, with core revenue increasing 4.0%. Management pointed to strong execution and a transition to a solutions-based sales approach as key drivers.
- Animal Safety: This segment faced significant headwinds, with revenue falling 20.1% to $54.5 million. CEO Mike Nassif attributed the decline to "several third-party, supply-based setbacks," which disrupted production and deliveries. The company is actively working to resolve these supplier qualification and planning issues.
Updated Guidance and Market Reaction
Perhaps the most critical element for investors was the company's updated full-year fiscal 2026 guidance. Neogen raised its revenue outlook but maintained its adjusted EBITDA forecast, implying pressure on profitability.
- Updated Revenue Guidance: $857 - $860 million (raised from $845 - $855 million)
- Adjusted EBITDA Guidance: Approximately $175 million (unchanged)
The decision to hold the EBITDA target flat while raising the revenue range suggests that cost pressures, including those from the troubled Animal Safety segment and ongoing manufacturing transitions, are expected to persist. This outlook appears to be the primary catalyst behind the stock's negative pre-market reaction, which showed a decline of approximately 10.9%. The market is likely interpreting the maintained profit guidance as a sign that near-term operational challenges will continue to weigh on earnings potential, overshadowing the quarterly earnings beat.
Strategic Developments and Outlook
Beyond the quarterly numbers, Neogen announced several strategic moves. The company is progressing with a global review of its go-to-market strategy and remains on track to complete the transition of its key Petrifilm manufacturing line by November 2026. Notably, Neogen has entered into an agreement to sell its global Genomics business to Zoetis Inc. for $160 million, a move intended to streamline operations and strengthen the balance sheet, with proceeds anticipated to be around $140 million after taxes and fees.
Looking ahead, analyst estimates for the coming periods provide a benchmark. For the full fiscal year 2026, the sales consensus sits at approximately $867.6 million, which is slightly above the high end of Neogen's newly raised guidance. For the next quarter (Q4 2026), analysts are projecting sales of about $216.4 million.
For a detailed look at Neogen's historical earnings performance and future analyst projections, you can review the data on its earnings and forecast pages.
Conclusion
Neogen's third-quarter results underscore a company in transition, navigating clear operational challenges while demonstrating underlying strength in its core food safety franchise. The earnings beat is a positive signal, but the market's focus has shifted to the persistent issues in the Animal Safety segment and the implications of a flat profit outlook for the year. The success of Neogen's strategic initiatives—resolving supply chain problems, completing its manufacturing transition, and effectively deploying capital from the genomics divestiture—will be crucial in determining whether the current stock reaction is a temporary setback or a reflection of longer-term concerns.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor does it recommend any investment action. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.